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Abs tract
Sign ificant progress has been made over the past decade in the use qfant ipsychotic medication.
An improved understa nding ofneuroleptic side effects has led to the development qf new clinical
strategiesfor dosing tradit ional medications. T raditi onal medicat ions have become widely used in
depot preparations. Risperidone, a new medication with an improved side dfect profile, has recentl y
become avai lable. Clozapine, a novel medication , has entered widespread use. Th e use of these new
clinica l technologies is briefly discussed, along with the implications they hate for the role ofthe
psychiat rist in community mental health setti ngs.
Neuroleptic medi cation has been wid ely used in th e treatment of schizophre nia
since th e 1950 's. O ver th e past decad e, howeve r, we have seen significan t advan ces in
our unde rstanding of th ese medi cation s ( 1,2). O nly re cent ly, for inst an ce, has the
effect of do se on efficacy a nd side effects been elucida te d . This has led to more refined
dosing strategi es, with a n incr eased appreciation for th e toxic effec ts of these
medi cations. Lon g acting decanoat e pr ep aration s have also beco me bett e r und er-
s too d, a nd have en te re d widespread clinica l usc. Indeed , deca noa te pr eparation s can
now be see n as th e pr eferred medi cation for man y chro nica lly ill pat ients. Fin ally, a
grea t deal of excite me nt ha s been ge ne ra ted by t he develop men t of novel medi ca-
tion s with incr eased efficacy a nd decr eased side effec ts. C loza pin e a nd risperidone
have become wide ly ava ilable, and expe rime n ta l medi cation s suc h as ola nzapine are
show ing grea t promise . The availability of new medi cation s has combined with a n
improved understanding of psych opharmacology to make optimal me d icat ion ma n-
age me nt more com plex. This pr esents a un iqu e opport un ity for psychiat ris ts to tak e
a leadership rol e in com m unity mental health treatment org a niza t ions as a skilled
psychopharmacologi st .
DOSING ST RATE GIES
Only recently have re searc he rs begun to elucida te th e effec t of neu roleptic dose
on response and toxi ci ty (3,4) . Pr eviously th ere was a gen eral belief th at more was
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better, and that littl e harm cou ld come from high d oses. Indeed , cl inica l strategies,
su ch as " ra pid neuroleptization" advocat ed the use of high-dose treatment of acu te
psychosis. Thes e approaches did not withstand ca re fu l study (5) . Indeed , research e rs
have recently found a dose-r esponse cu rve for conve nt iona l neurolept ics in which
moderat e doses produce m aximal improvement (6) . The optimal dose for acu te
psychosis appears to be in th e range of 10-1 5 mg per day of hal op eridol (4,7) , and
some studies sugges t that patients improve on substantially lower do ses (8) . W hile
there has been less res earch on th e dose-response cha rac te r istics of o ther conven-
tional neuroleptics, a similar rel ationship has been sugges te d for fluph enazine ,
trifluoperazine and thiothixen e (9) . While typi cal dosa ge levels va ry bet ween differ-
en t neuroleptics, conve rs ion factors allow doses of eac h neuroleptic to be un derstood
as an approximate haloperidol eq u iva le nt dose ( 10).
Of cou rse , th ere is th e rare patient who ac tua lly ben efits fro m more t han 10 or
15 mg per day of haloperidol. Why, therefore, take a cha nce by tapering a patien t 's
dose? There are several very convincing reasons for tapering doses, with th e goal of
esta blishing th e minimum effec t ive dose for eve ry patient. First , it is likely th a t many
patients on very high dos es of neuroleptic a re, in fac t, minimall y respo nsiv e or
nonresponsive to neuroleptics. Between 10 and 40% of people with schizo phrenia a re
nonrespon sive to traditional neuroleptics (II). These patients ofte n get t he ir dos es
st eadily incr eas ed in an attempt to con t ro l persist ent sym pto ms, resulting eventually
in sedation and che m ica l restraint. Often these patients ca n be managed q uite well
with low dose neuroleptic combined with behavioral therapies suc h as social ski lls
training (12) or a potent benzodiazepine su ch as clonazep am ( 13) .
The ri sk of tardive dyskinesia is well known, a nd is th ou ght to occur in
a pproxima te ly 4% of patients for eve ry year of neuroleptic exposure ( 14) . While
tardive dyskinesia has not been proven to be dose-relat ed , th ere a re strong theoreti-
ca l and expe r imen tal reasons to beli eve th at dose may play a n import ant ro le ( 15).
There has als o been a n incr eased recognition of th e ac u te side effects of oral
neuroleptics. Acute ex t ra pyra m ida l side effec ts, su ch as dyst on ias , are we ll-known
a nd do se-related. Akathisia is do se-related , ca n be difficult to trea t , and may lead to
behavioral disturbances and treatment non compliance (4). Other com mon sid e
effec ts, including apathy, a nhe do nia, and akinesia, a re sim ila r to th e nega tive
sym ptoms of schizophrenia , and th e refore easy to ove rlook. While so me of th ese sid e
effec ts can be a me lio ra te d with m edication, others, suc h as sexua l dysfunct ion , are
ge ne ra lly resi st ant to a ny thing other th an a cha nge of dose or medi ca tion . Finally,
th ere is recent evide nce that vocation al a nd soc ia l fun cti oning worsen s on higher
doses of neuroleptics (16,17).
Sin ce neuroleptics ca n have adve rse effec ts a t eve n m od erat e doses, clinicians
need to titrat e ca re fully dose and effec t ( 18) . Even if a mod erat e dosage is effect ive in
producing a rem ission of positive sym ptoms, a lower do se may be adequat e for
averting a m ajor relapse. However, intermitt ent dosing or " d rug holidays" have been
shown to significantly increase th e cha nce of relapse , a nd a re not ge nerally recom -
mended (2) . One should assum e th at , a t a ny give n tim e, th ere is a n opt imal dose for
eac h patient whi ch ca n be found by weighing ben eficial a nd adverse effects . It is not
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uncommon for this optimal do se to be below th at need ed to remove all psych oti c
sym pto ms. Maximal functioning m ay ofte n be ac hieved even wh en th e pa ti en t
con t inues to hav e so me psych otic sym ptoms. The refore , it is cruc ia l that pati en ts be
ta ugh t to recogn ize sym pto ms a nd side effects, a nd to communicat e th ese to th e ir
phys icia n. While this so rt of educa t ion can be ti m e co nsuming, it has been shown to
red uce re la pse ( 19) . Pat ients can be ta ught to ra te eac h important sympt om a nd
side-e ffec t on a dail y basis. When th e ph ysician uses th is in fo r ma t ion and compl e tes a
Bri ef Psychiatric Rating Scal e (20) a t each visit , th e " minimal effe c tive do se" ca n be
readily det ermined . This dose , whe n fa ithfu lly used , a llows th e pat ient to niaximize
fun ctioning and qu al it y of life .
There is good reason to beli eve th at the effectiv e us e of neuroleptic medica tion
requi res an integration of psycho p harmaco logy and psych osocial reh abili tation (2 1).
Fo r inst ance, psychi atri st s need to kn ow how a patie n t is fun ctioning in orde r to
ar rive a t a n optimal m edicat ion regimen. Also, pa tien ts need to have access to
int ensive psych oeducationa l progra ms th at teach the m about th e symptoms of th eir
mental illness and the side effec ts of th eir m edica tion. This ed uca tion may, in m an y
organiza tions, be mos t cost-effect ively perform ed by a non-psychiatrist. These co lla bo-
rative approaches req uire, howeve r , that the psychiatrist is available to supe rvise
ot he r cl in icians about med ication and com m unica te with th em regarding th e curre nt
sta tus of re habilitat ion effo r ts . T h is co lla boration is not likely to occur if th e
psychiat ri st is not a n int egra l me mbe r of th e treatmen t team. Community ment al
hea lth organiza t ions th at limit psychi atri st s to sig ning prescr ip ti ons are unlikely to
provide the fu ll ben efit s of m od ern psyc ho pharmacology to their patients.
DEPOT PREPARATIONS
Inj ect able d ep ot neu roleptics sho uld be conside red in a ll people with chro nic
psych otic illn ess, a nd shou ld gu ide th e initial cho ice of ora l med ica t ion. Use of
inj ect able m edication is not limited to the typical " non-com plia n t" pati ent. Even
co m plia n t pa ti ents have exace rba t ions, a nd the paranoia a nd di sorganization th at
accompanies th ese often lead to d iscont inuat ion of medicat ion. This may incr ease th e
len gth and severi ty of th e re lapse. Inj ectable med ications also a llow more pr ecise
ti t ration of dose a nd respon se , since the de livery of medication to th e brain is more
re liable th an wit h oral m edication and in termitt ent " m issing" of a do se is less of an
issu e. Finall y, intramuscula r medicat ion can result in less severe ext ra pyra m ida l side
effects than ora l preparation s. Pati ents sho uld be told th a t injectable medi cation will
lower t he ir ri sk of relapse a nd can red uce their total long-t e rm neuroleptic expos ure.
When arriving at a m illigram dose for d epot m edication, it is reasonable to begi n
wit h a I : I oral-to-decanoate conve rsion for fluphenazine decanoat e given eve ry two or
th ree wee ks. Si m ila r ly, it is reasonable to begin with a I: I0 oral-to-decanoat e
conve rsion for halop eridol d ecanoa te given mon t hly (22). For example, a patient who
is taking 5 mg ha lop eridol dail y wo uld be expected to req u ire ro ugh ly 50 mg of
haloperidol decanoat e pe r m onth. W hile there is variation be tween patients a nd
d isagreem ent abo ut opt imal conve rsion fac tors, th ese ratios provide good star t ing
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points. Aft er beginning d ecanoat e prep aration s, one must be sure to con t inue ora l
m edica ti on s for a t lea st one to two months, sinc e it ca n tak e 3 to 5 doses of dccanoat c
before a ste ady sta te is reach ed (23 ) . While techniqu es have been d eveloped for
" loa d ing" pat ients with d ecanoat e wi thout co ncom itan t use of oral medica t ion,
grad ua l transition from oral to decanoat e m edi cation produces th e most consiste n t
plasm a co nce nt ra t io ns (24) .
The lon g half-li fe o f decanoa te a lso di ct at es that upwa rd or downwa rd titration
of d ecanoate dose , while important , sho u ld be don e eve ry 3 to 6 mon ths. For the sam e
reason, psychotic exace rba t ions whil e on decanoat e should be treated by a ugmenting
with oral m edication , not neces sarily incr easin g d ecanoat e dose. Fin all y, it is impor-
tant to be aware of the need for training in th e inj ection of the viscou s decanoat e
pr epara tion s. When typical int ramuscular inj ection techniques are used th e decano-
a te prep arations ca n leak sig nifica n t ly a t th e inject ion site . Pract iti oners should,
therefore , use a " Z-t rac king" techniqu e to ens u re cons is te n t medicat ion del ive ry
(25) . Z-Tracking involves manuall y movin g superficia l t iss ue a nd m uscl e before
decanoate inj ection so th at the needl e t rack does not re main con t iguous with th e
inj ecti on site . Us ing a small ga uge need le may a lso hel p re d uce leak age.
NOV EL MEDI CATIONS
Stud ies show th at ro ug hly one -th ird of people with sc hizoph renia show litt le
improv ement with tradition al neu rol eptic me dica t ions ( I I). These pat ients hav e
been termed " ne urole pt ic nonresp onders" (26) . While st ra tegies su ch as cha nging to
a different neurolept ic, using a high do se, or a ug men t ing with lithium occasiona lly
help non-responsive patients, th ey ge ne rally p rov e in effecti ve (27) . These nonrespon-
sive patients have, however, been dram aticall y helped by th e developm ent of novel
ant ipsyc ho t ic m edi cation s . This di scu ssion will focus m ainl y on c1ozapine, sin ce this is
th e only m edi cation that has been clearly sho wn to be more effect ive than other
an t ipsyc hot ic medicat ion s. An other recently ava ila ble a n tipsyc ho t ic me dic a tion is
risperidone, a n agent with significa n t a n tagonis t ic ac t ivity a t dop a mine, serotonin ,
a nd alpha-adren ergic receptors. It has been sho wn to have a unique sid e-effe ct
pro file , with a reduced liability for ext ra pyram idal sym ptoms a t efficac ious doses
(28). The one la rge study exam ining thi s m edi cation found th at r isp eridon e als o
improved negative sym p to ms, however, furth er research will be need ed to de te rmi ne
wh et her thi s is secondary to a lower level of parkinsonian side-effec ts. In a ny case , as a
result of ri sp eridon e's sign ifica n t a n t i-sero to ne rgic ac t ivity, it has a uniqu e sid e-effect
profil e a nd has proven to be well tolerat ed . It has, on this basis, en te re d wid espread
use as a n important cl in ica l tool.
C loza pine, while more diffi cult to usc than ot he r a n ti psyc ho t ic medications, is
clinicall y fairly we ll understood . An y co m m un ity mental health organization tha t
treat s more th an a few peopl e with schizo phre nia sho uld be using c1ozap ine. While
m uc h press has been made a bo u t clozapine 's efficacy wit h the " nega t ive" or defici t
sym pto ms of sc hizoph renia , in fact a ll neu roleptic med ica tions t reat negative sym p-
toms to so me d egree (29). C lozapinc's use fulness appears to a ris e from th e fa ct tha t
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it t reats both negative and posruve sym pto ms more effec tiv e ly tha n an y othe r
available antipsychotic m edication (30,31). While the efficacy of ri sp eridone has not
ye t been adequat ely com pare d to c1ozapine , preliminary clinical expe r ience suggests
that it may not be as effec t ive in se ve re ly ill patients. Cl ozapine is a lso useful because
it is th e only cu r re n t ly available antipsychotic medication th at ca uses ve ry few or no
parkinsonian side effec ts . Finall y, ex te ns ive expe r ie nce with clozapine indica tes th a t
it ca uses very little o r no tardive dysk in esia . In fact , tardive dyskinesia oft en improves
with cloza pine treatment (32), making this th e m edication of choice for people with
psych ot ic illnes s and seve re or progressive tardive movement d isorders.
Given th e risk of agra nu locyto sis, c1ozapine 's use sho u ld usuall y be lim ited to th e
following clinical situations: I) inadequat e response to co nve ntional a n tipsychotic
m edications, 2) di sabling or progressive tardive dyskinesia , o r 3) unmanageable side
effects on other a nt ipsycho tic m edi cation s (33). Inadequat e res po ns e to co nve ntio na l
agents is oft en int erpret ed as m eaning that significant positive symptoms have
persist ed despit e ade q ua te tri al s of two different neuroleptic m edi ca ti ons. T he re is
no reason to su sp ect that cloza pine should be limited to pati en ts with a ny part icu la r
psychotic diagnoses. Clozapine has be en shown to be effec t ive in both sch izophren ia
and sc hizoa ffec t ive di sorder, a nd has been success fu lly used in refr acto ry bipola r
di sorder and borderline personality di sorder with psych osis (34, 35). The only absolu te
cont ra ind ica t ions to cloza pine are a hemat olo gic di sorder pr edi sp osi ng to gra nu locy-
topenia , previous leukop enia with c1ozapine , a nd co matos e stat es.
C lozapine ca n ca use a number of side effec ts (36). Com mon mi nor side effects
include sedation, excessive drooling and weight ga in . Sedation often occu rs with
dosa ge increases , ge ne ra lly resolves with tim e, and ca n be minimi zed by giving th e
ent ire dail y dose of clozapine a t bedtime. Drooling ca n be managed by placing a towe l
on th e pillow at night, or, if necessary, by using a n a nt icho line rg ic medicat ion.
W eight ga in is managed with di et a ry modifi cation and ex e rcis e. Less fr equen t sid e
effec ts include tach ycardia , increased body temperature and orthos tat ic hypo tension .
Tachycardia and temperature increas es a re usu all y mild and ofte n do not require
intervention. They must , however, be differentiat ed fro m th e more seriou s (a nd ra re )
Neuroleptic Mali gnant Syndrome. Orthostatic hyp ot en sion can oft en be managed by
having th e patient cha nge position slowly, a nd increase fluid a nd salt intak e. Overall ,
c1ozapine 's minor side-e ffec ts a re usually easy to manage. \"'ith th e except ion of
weight gain , th ey ge ne rally resolve with time a nd a re less seve re if t he medi cat ion
do se is titrat ed up slowl y. If a tte nde d to a pprop ria te ly, th ey sho uld rarely lead to
m edication di scontinuation. In fact , most patients find c1ozapine 's side-effects to be
preferable to those associat ed with trad itional neuroleptics.
Serious side effec ts of cloza pine include respirat ory a r res t, se izu re , and agranu-
locyt osis. Respiratory a r res t is quit e rare, a nd see ms mo re likely wit h the firs t dose
a nd wh en th e patient is taking a respiratory d epressant. For this reason, pa tient s
sho uld not be on benzodiazepines wh en sta r t ing c1ozapine. Also, a ll pa tie nt s mu st
star t a t a dail y dose of 12.5 mg, a nd must rest art a t this dose aft er be ing off cloza pine
for more th an on e day. Seizures occur in 2-3% of patients a t low doses (less th an 450
mg) , in 5- 6% of patients a t higher doses (mo re th an 650 mg) , a nd appear to be
THE NEUROLEPT IC TREATMENT OF SCHIZOPHRENIA 23
re la ted to t he ra te of dosage increase. C lozapine may not be us ed a t do ses above 900
mg per day. If a seizure occurs, the clozapine dose should be cu t in hal f and the
patient se n t for neurologi c eva lua t ion. If this neurolo gic eva lua t ion is normal,
valproat e ca n be begun a nd th e cloza pine dose slowly increased as needed. As with
se izu re s ca used by traditional neurol eptics, the se izu res with clozapine are often
readi ly co nt rolled .
Agranu locytosis occurs in about 1% of patients (37) , and death due to agran ulo-
cytosis has occurred in about 0.05 % of patients. Deaths du e to agranulocyt osis may,
how ever, be more than offs et by reductions in morta lit y due to improved t reat ment of
sch izophrenia (38). Because a ll patients in th e U n ite d St ates must have thei r whit e
blood ce ll coun t test ed weekl y before receiving th eir medication , agranu locytosis is
readily detect ed a nd treat ed. Be tween February 1990 a nd May 1992 140 cases of
agranulocytosis occurred, and th ere were 7 deaths relat ed to agranu locytos is. All of
th es e deat hs occurred in pat ients who were a t o r above 40 years old (39). The first
death was wide ly reported, a nd occurred in a patient wh o was a lso tak ing car-
bamazepine (40). Carbamazepine , a nd o the r m edication s th a t ca use le ukopenia,
should be used with ca ut ion in patients on c1ozapine .
Over th e year ending April 1992 , twenty-three th ou sand patients we re enrolled
in cloza pine treatment sys te m s. Thes e syst ems include a psychi at ri st , a ph a rmacist
and a labora tory, and req uire a great d eal of paperwork a nd ad m inis t ra tive effort.
For this reason, pharmacists have cre a te d cons u lt ing groups whi ch co mple te th e
paperwork a nd other ad m in ist ra t ive work asso ciat ed with c1ozapine . Our cli nicians
have had success working with a loca l cons ult ing bu sin ess th at cha rges the pa tient
abo u t 20 per week for th eir servi ces (4 1). They have mad e clozapine as easy to us e as
a ny o the r neuroleptic m edication, and have facilit at ed ou r use of clozapine at a loca l
public m ental health clin ic.
There have been a number of prom inen t obst acl es to th e use of cloza pinc in
public m ent a l heal t h systems (42). Most of th e people who wou ld ben efit from
cloza pine have se ve re ch ro nic sc hizophre nia, and mo st of th ese peopl e are t reat ed in
these public sys te ms. U nfort u na te ly, th e ava ilability of clozapine in th e public se ctor
has been gu ide d more by ad m inist rat ive than clinical forces. These pu blic systems
have been accustome d to ca ring for th e se rious ly ill while spe nd ing remarkably littl e
money on psychiatric treatment. Patient s are oft en seen eve ry one to th ree months by
psychiat rists who are a llowed on ly a few m inut es per patien t to pr escribe m edi cat ion .
Minimizing the ro le of psychiatrists has m ad e the introduction of clozapine tragicall y
slow in m any publ ic mental health clinics.
Public sys te ms' relu ctance to ado pt new clinical technologies suc h as clozapine
ca n be ove rcome by pressure from psychiatrist s a nd co ns umer organizat ions . The
National Alli ance for th e Mentally III was instrumental in th e d ecision by th e federal
gov ernment to force sta te Medi caid programs to pay for c1ozapine. U nfort u na tely,
many stat e and local governments have not implem ent ed th e clinica l reforms
necessary to actually make cloza pine ava ila ble in public clinics. The use of clozapi ne
in th es e clinics requires ed uc a t ion of clinic sta ff, a n increase in cl inica l a nd adrn inis-
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trat ive resources fo r se r io us ly ill pat ients, a nd su pervision of a mul ti-discipli na ry
team by a psychiatrist wh o will prescribe clozapine.
C ONC LU SIO N
Over the past decade , we hav e wi tnessed signifi cant progress in th e psyc hophar-
m acologic m ana gem ent of psych otic di sord ers. Min im al e ffec t ive dosing , d epo t
m edication, a nd novel agents have sig n ifica n t ly improved the res ponse of sch izo phre-
n ia to treatment. Thes e new cl in ical t echnologi es hav e not , however, bee n adop te d by
many of the public orga n iza t ions that ca re for these patient s. This lack of availa bi lity
o f s ta te-of- t he-a rt treatm ent has ra ised sig n ifica n t ques tio ns a bo u t th e qualit y of care
deli ve red in publ ic sys te ms (+3) . Improving this quality will begin wi th psychiat ris ts
a nd consu mer advoca tes who in sist on the ava ila b ility of these new clinica l te ch-
ruq u es ,
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